Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
Top Cited Papers
- 29 September 2014
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 14 (11) , 1090-1095
- https://doi.org/10.1016/s1473-3099(14)70920-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus InfectionAntimicrobial Agents and Chemotherapy, 2014
- Middle East Respiratory Syndrome Coronavirus: A Case-Control Study of Hospitalized PatientsClinical Infectious Diseases, 2014
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirusJournal of Infection, 2013
- Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapyInternational Journal of Infectious Diseases, 2013
- A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild caseInternational Journal of Infectious Diseases, 2013
- Hospital Outbreak of Middle East Respiratory Syndrome CoronavirusNew England Journal of Medicine, 2013
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012Intensive Care Medicine, 2013
- Severe acute respiratory syndrome: report of treatment and outcome after a major outbreakThorax, 2004
- The Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003